ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2399

Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis
Abstract Number: 2495

Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Abstract Number: 2428

Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Abstract Number: 0163

Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims
Abstract Number: 1312

Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Abstract Number: 2591

Under Assault: Ongoing Brain Dysfunction Identified on Resting State-functional MRI (rs-fMRI) in SLE Patients in Clinical Remission
Abstract Number: 0809

Underserved by Rehabilitation: Characteristics Among Adults with Rheumatoid Arthritis
Abstract Number: 2521

Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?
Abstract Number: 1204

Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
Abstract Number: 0787

Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry
Abstract Number: 0258

Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation
Abstract Number: 0325

Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey
Abstract Number: 0159

Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Abstract Number: 0650

Understanding the Employment Landscape in People with Systemic Sclerosis
Abstract Number: 1052

Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].